Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
45 hedge funds and large institutions have $15.5M invested in Nymox Pharmaceutical Corp in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 3 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
0.04% more ownership
Funds ownership: 7.7% → 7.74% (+0.04%)
0% more funds holding
Funds holding: 45 → 45 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
9% less capital invested
Capital invested by funds: $17.1M → $15.5M (-$1.6M)
91% less call options, than puts
Call options by funds: $251K | Put options by funds: $2.79M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$782K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$300K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$181K |
| 4 |
Wolverine Trading
Chicago,
Illinois
|
+$157K |
| 5 |
State Street
Boston,
Massachusetts
|
+$94.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$549K |
| 2 |
Renaissance Technologies
New York
|
-$240K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$176K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$83.3K |
| 5 |
Goldman Sachs
New York
|
-$48.2K |
NYMX Hedge Fund Activity: Q3 2017 in Review
45 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q3 2017, worth a combined $15.5M — down 9.4% from $17.1M a quarter earlier.
Fund positioning in NYMX was balanced in Q3 2017: 3 funds opened new positions, 3 closed out, 15 added to existing stakes and 13 trimmed.
The largest buyer was Northern Trust, adding an estimated $782K. The largest seller was Morgan Stanley, cutting an estimated $549K.
- 45 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $15.5M of Nymox Pharmaceutical Corp stock for Q3 2017, down 9.4% quarter-over-quarter.
- 3 funds opened new Nymox Pharmaceutical Corp positions in Q3 2017 and 3 closed out, a net change of 0 holders.
- The largest Nymox Pharmaceutical Corp buyer in Q3 2017 was Northern Trust, an estimated $782K added.
- The largest Nymox Pharmaceutical Corp seller in Q3 2017 was Morgan Stanley, an estimated $549K sold.
Based on aggregated 13F filings for Q3 2017.